First Light Asset Management LLC cut its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 29.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,200,508 shares of the company’s stock after selling 489,669 shares during the quarter. Crinetics Pharmaceuticals comprises about 4.7% of First Light Asset Management LLC’s holdings, making the stock its 3rd largest position. First Light Asset Management LLC owned about 1.52% of Crinetics Pharmaceuticals worth $53,771,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Comerica Bank bought a new stake in Crinetics Pharmaceuticals during the 1st quarter valued at $33,000. Quarry LP bought a new stake in shares of Crinetics Pharmaceuticals during the 4th quarter valued at $36,000. Quest Partners LLC purchased a new stake in Crinetics Pharmaceuticals during the 2nd quarter worth about $42,000. Amalgamated Bank lifted its holdings in Crinetics Pharmaceuticals by 20.8% during the 2nd quarter. Amalgamated Bank now owns 2,692 shares of the company’s stock worth $121,000 after purchasing an additional 464 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. bought a new position in Crinetics Pharmaceuticals in the 1st quarter worth about $200,000. Institutional investors own 98.51% of the company’s stock.
Insiders Place Their Bets
In other news, COO Jeff E. Knight sold 956 shares of the stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $44.38, for a total transaction of $42,427.28. Following the completion of the sale, the chief operating officer now owns 52,580 shares of the company’s stock, valued at $2,333,500.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, COO Jeff E. Knight sold 956 shares of Crinetics Pharmaceuticals stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $44.38, for a total value of $42,427.28. Following the transaction, the chief operating officer now directly owns 52,580 shares of the company’s stock, valued at $2,333,500.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Jeff E. Knight sold 27,000 shares of the stock in a transaction on Monday, July 15th. The shares were sold at an average price of $55.00, for a total transaction of $1,485,000.00. Following the sale, the chief operating officer now directly owns 51,653 shares of the company’s stock, valued at approximately $2,840,915. The disclosure for this sale can be found here. Insiders have sold 143,551 shares of company stock valued at $7,155,329 in the last ninety days. Company insiders own 6.00% of the company’s stock.
Analysts Set New Price Targets
View Our Latest Stock Analysis on CRNX
Crinetics Pharmaceuticals Stock Performance
Shares of Crinetics Pharmaceuticals stock opened at $50.42 on Tuesday. Crinetics Pharmaceuticals, Inc. has a 52-week low of $25.35 and a 52-week high of $55.78. The company has a fifty day moving average of $52.33 and a 200-day moving average of $48.11. The stock has a market capitalization of $3.98 billion, a price-to-earnings ratio of -13.34 and a beta of 0.63.
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.08). The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.47 million. The firm’s revenue for the quarter was down 59.6% on a year-over-year basis. During the same period last year, the firm posted ($0.94) EPS. On average, equities research analysts forecast that Crinetics Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.
Crinetics Pharmaceuticals Company Profile
Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.
Featured Articles
- Five stocks we like better than Crinetics Pharmaceuticals
- The 3 Best Fintech Stocks to Buy Now
- Rate Cut Shockwaves: Which Bank Stocks Will Rise or Fall?
- Short Selling: How to Short a Stock
- S&P 500 Shake-Up: New Entrants Driving Market Momentum
- Overbought Stocks Explained: Should You Trade Them?
- Don’t Overlook Mosaic’s Challenges—They Might Spark Opportunity
Want to see what other hedge funds are holding CRNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report).
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.